Mary Motyl

Mary Motyl publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Mary Motyl sits on this spectrum.

Mary Motyl D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Mary Motyl sits on this spectrum.

Best Publications

• Platensimycin is a selective FabF inhibitor with potent antibiotic properties

  Jun Wang;Stephen M. Soisson;Katherine Young;Wesley Shoop;Wesley Shoop

  1001
  Citations

• Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties.

  Jun Wang;Srinivas Kodali;Sang Ho Lee;Andrew Galgoci

  465
  Citations

• Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

  M.A. Pfaller;D.J. Diekema;D. Andes;M.C. Arendrup

  377
  Citations

• Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.

  Johan A Maertens;Galia Rahav;Galia Rahav;Dong-Gun Lee;Alfredo Ponce-de-León

  252
  Citations

• Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species

  Frank C. Odds;Mary Motyl;Roberto Andrade;Jacques Bille

  200
  Citations

• Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome

  Unknown

  188
  Citations

• Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.

  M. A. Pfaller;D. J. Diekema;M. A. Ghannoum;J. H. Rex

  185
  Citations

• Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.

  Michael A. Pfaller;David Andes;Maiken C. Arendrup;Daniel J. Diekema

  179
  Citations

• Global Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 Gene.

  Yasufumi Matsumura;Johann D.D. Pitout;Ryota Gomi;Tomonari Matsuda

  178
  Citations

• Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.

  A. L. Colombo;J. Perfect;M. DiNubile;K. Bartizal

  171
  Citations

• In Vitro Activity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria

  Elizabeth B. Hirsch;Kimberly R. Ledesma;Kai Tai Chang;Michael S. Schwartz

  169
  Citations

• In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program).

  Sibylle H. Lob;Meredith A. Hackel;Krystyna M. Kazmierczak;Katherine Young

  166
  Citations

• Genomic Epidemiology of Global Carbapenemase-Producing Enterobacter spp., 2008-2014.

  Gisele Peirano;Yasufumi Matsumura;Mark D. Adams;Patricia Bradford

  150
  Citations

• Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates

  Cristina Jiménez-Ortigosa;Padmaja Paderu;Mary R. Motyl;David S. Perlin

  142
  Citations

• In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested Against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods

  Michael A. Pfaller;Shawn A. Messer;Mary R. Motyl;Ronald N. Jones

  118
  Citations

• Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy

  M. J. DiNubile;I. Friedland;C. Y. Chan;M. R. Motyl

  117
  Citations

• Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)

  Michael A Pfaller;Shawn A Messer;Mary R Motyl;Ronald N Jones

  117
  Citations

• In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa

  Katherine Young;Ronald E. Painter;Susan L. Raghoobar;Nichelle N. Hairston

  115
  Citations

• Genomic epidemiology of global Klebsiella pneumoniae carbapenemase (KPC)-producing Escherichia coli.

  N. Stoesser;A.E. Sheppard;G. Peirano;L.W. Anson

  114
  Citations

• In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014

  James A. Karlowsky;Sibylle H. Lob;Krystyna M. Kazmierczak;Robert E. Badal

  111
  Citations